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ABSTRACT
Introduction: We assessed the Aurora A kinase inhibitor,
alisertib, plus paclitaxel (henceforth referred to as alisertib/
paclitaxel) as second-line treatment for SCLC.
Methods: In this double-blind study, patients with relapsed
or refractory SCLC were stratified by relapse type (sensitive
versus resistant or refractory) and brain metastases and
randomized 1:1 to alisertib/paclitaxel or placebo plus pacli-
taxel (henceforth referred to as placebo/paclitaxel) in 28-day
cycles. The primary end point was progression-free survival
(PFS). Associations of c-Myc expression in tumor tissue
(prespecified) and genetic alterations in circulating tumor
DNA (retrospective) with clinical outcome were evaluated.
Results: A total of 178 patients were enrolled (89 in each
arm). The median PFS was 3.32 months with alisertib/
paclitaxel versus 2.17 months with placebo/paclitaxel (haz-
ard ratio [HR] ¼ 0.77, 95% confidence limit [CI]: 0.557–
1.067, p ¼ 0.113 in the intent-to-treat population versus
HR ¼ 0.71, 95% CI: 0.509–0.985, p ¼ 0.038 with corrected
analysis applied). Among 140 patients with genetic alterna-
tions, patients with cell cycle regulator mutations (cyclin-
dependent kinase 6 gene [CDK6], retinoblastoma-like 1 gene
[RBL1], retinoblastoma-like 2 gene [RBL2], and retinoblas-
toma 1 gene [RB1]) had significantly improved PFS with
alisertib/paclitaxel versus with placebo/paclitaxel (3.68
versus 1.80 months, respectively [HR ¼ 0.395, 95% CI:
0.239–0.654, p ¼ 0.0003]), and overall survival (7.20 versus
4.47 months, respectively [HR ¼ 0.427, 95% CI: 0.259–0.704,
p ¼ 0.00085]). A subset of patients with c-Myc expression
showed significantly improved PFS with alisertib/paclitaxel.
The incidence of grade 3 or higher drug-related adverse
events was 67% (58 patients) with alisertib/paclitaxel
versus 22% (25 patients) with placebo/paclitaxel. Twelve
patients (14%) versus 11 (12%) died on study, including
four versus zero treatment-related deaths.
Conclusions: Efficacy signals were seen with alisertib/
paclitaxel in relapsed or refractory SCLC. c-Myc expression
and mutations in cell cycle regulators may be potential
predictive biomarkers of alisertib efficacy; further pro-
spective validations are warranted.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Phase II; Aurora A kinase; Alisertib; Paclitaxel;
SCLC
Introduction
SCLC is an aggressive malignancy, accounting for
13% to 18% of all lung cancer diagnoses.1,2 For many
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patients with SCLC, the outlook is bleak. In treated
extensive-stage SCLC, the median overall survival (OS) is
just 7 to 12 months.3,4 The prognosis for relapsed or
refractory SCLC is more dismal, with a median OS of 4 to
5 months.5
There is a strong correlation between the efficacy of
second-line therapy and the quality and duration of
response (DOR) to initial treatment (sensitive versus
resistant or refractory relapse).6 Response rates are
particularly poor (10%) in patients with resistant or
refractory disease who relapse 3 months or less from the
end of initial therapy.5 Patients with platinum-sensitive
disease (relapse >3 months from end of initial ther-
apy) have a relatively better outcome (response rate
w25%).5
Because of poor responses to current treatments,
there is a critical unmet medical need in patients with
SCLC, thereby justifying efforts to evaluate novel tar-
geted agents (with validated predictive biomarkers).7,8
One potential target is Aurora A kinase (AAK), a key
regulator of mitosis.9 AAK is amplified or overexpressed
in several solid tumors, including SCLC, and may play a
role in tumorigenesis.10,11 Inhibition of AAK leads to
disrupted mitosis and cell death, reduced proliferation,
and induction of apoptosis in SCLC cells.10,12
Amplification of v-myc avian myelocytomatosis viral
oncogene homolog gene (MYC) in SCLC cell lines is
associated with improved sensitivity to Aurora kinase
inhibitors.13,14 Amplification and overexpression of the
MYC gene family occurs in 18% to 31% of SCLCs and is
more common in chemorefractory disease.15 The gene
product, c-Myc (a transcription factor), binds directly to
AAK, and inhibition of this interaction by AAK inhibitors
results in c-Myc degradation and cell death.16,17 Thus,
the Myc–AAK protein complex represents an actionable
drug target for AAK inhibitors.
Alisertib (MLN8237) is an investigational, selective,
oral, small molecule AAK inhibitor that has been
studied in various solid tumors and hematologic malig-
nancies.18-23 Single-agent activity was demonstrated in a
phase II study of patients with relapsed or refractory
solid tumors, including SCLC (n ¼ 48);23 in patients with
SCLC, the objective response rate (ORR) was 21% and
the median progression-free survival (PFS) was 2.1
months.23 On the basis of preclinical evidence of synergy,
alisertib plus paclitaxel (henceforth referred to as ali-
sertib/paclitaxel) was evaluated in patients with breast
and ovarian cancer19 and showed promise over pacli-
taxel alone, with PFS and ORR trending in favor of the
combination.19 Preclinical data have also shown ali-
sertib/paclitaxel synergy in SCLC; increased antitumor
activity with the combination versus with the single
agents was demonstrated in xenograft tumor models
derived from human SCLC cell lines and human SCLC
primary tumors (Takeda, data on file). The preclinical
and clinical data thus provided justification for this
phase II study of alisertib/paclitaxel as second-line
therapy for relapsed or refractory SCLC. As part of this
study, analyses were undertaken to assess the impact of
c-Myc protein expression and genetic alterations on
clinical outcomes.
Patients and Methods
Study Design
This multicenter, randomized, double-blind, placebo-
controlled phase II trial (NCT02038647) enrolled pa-
tients across 54 sites in the United States (19 sites),
Canada (three sites), and Europe (32 sites) from May 7,
2014, to October 26, 2015. The trial was conducted in
accordance with applicable regulatory requirements,
International Conference on Harmonization Good Clin-
ical Practice guidelines, and the ethical principles foun-
ded in the Declaration of Helsinki. Study documentation
was approved by the institutional review board and/or
independent ethics committee at each site. Patients
provided written informed consent.
Patients were randomized 1:1 to receive either ali-
sertib (40 mg by mouth twice daily for 3 weeks on days
1–3, 8–10, and 15–17) plus paclitaxel (60 mg/m2
intravenously on days 1, 8, and 15) or placebo (by mouth
twice daily as per alisertib) plus paclitaxel (80 mg/m2
intravenously on days 1, 8, and 15) in 28-day cycles. The
dosing schedule permitted maximal overlap of systemic
exposures between alisertib and paclitaxel while
providing sufficient treatment-free periods to allow re-
covery from toxicities associated with both agents.
Randomization was stratified by type of relapse after
primary treatment, based on the common definition for
each type5,6 (with sensitive defined as relapsed >90 but
<180 days after primary treatment and resistant or re-
fractory defined as relapsed 90 days after primary
treatment) and presence of brain metastases (yes versus
no) at study entry. Patients received treatment until
progressive disease, discontinuation because of toxicity,
loss to follow-up, study termination, protocol violation,
or patient withdrawal. The study team and site staff
responsible for assessing patients were blinded to
treatment assignment; participating sites were required
to designate a non-blinded study pharmacist for dose
preparations.
Patients
The study enrolled patients at least 18 years old with
a pathologically (histologically or cytologically)
confirmed diagnosis of SCLC. Patients were required to
have progressed within 180 days of last platinum dose,
after receiving a standard platinum-based chemotherapy
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regimen as first-line treatment, and to have measurable
disease per the Response Evaluation Criteria in Solid
Tumors version 1.1 within 2 weeks before randomiza-
tion. Other key inclusion and exclusion criteria can be
found in the Supplementary Methods.
End Points and Assessments
The primary end point was PFS (time from random-
ization to progressive disease or death), with patients
stratified by type of relapse after primary treatment
(sensitive versus resistant or refractory disease) and
presence of brain metastases. PFS was also analyzed in
patient subgroups according to baseline characteristics.
Secondary end points were safety and/or tolerability, OS,
ORR including complete response, disease control rate
(DCR: complete response, partial response, or stable
disease 8 weeks), and DOR. Exploratory end points
included correlative biomarker studies to evaluate the
impact of c-Myc expression and genetic alterations on
clinical outcomes (PFS and OS).
Extent of disease was evaluated according to the
Response Evaluation Criteria in Solid Tumors version 1.1
at screening, after every cycle for the first 6 months, and
subsequently every two cycles (between days 21 and
28) to assess disease response and progression; because
of the aggressiveness of SCLC, disease assessments were
performed more frequently than in common clinical
practice. Radiographic images (by contrast-enhanced
computed tomography or magnetic resonance imaging)
were assessed locally and submitted for central review if
the results were positive. For biomarker evaluations, c-
Myc expression was assessed by immunohistochemical
analysis of c-Myc expression in tumor tissue, and genetic
alterations were assessed retrospectively by next-
generation sequencing (NGS) of circulating tumor DNA
(ctDNA) from peripheral blood by using a custom
PlasmaSelect-R (Personal Genome Diagnostics, Inc., Bal-
timore, MD) targeted gene NGS panel (Supplementary
Table 1).
Details of follow-up for PFS and OS, and the methods
used for the biomarker assessments, are provided in the
Supplementary Methods. Toxicity was graded according
to the National Cancer Institute Common Terminology
Criteria for Adverse Events version 4.03. The use of
myeloid growth factors for the management of neu-
tropenia was not mandated but was permitted at the
discretion of the investigator if clinically indicated, ac-
cording to local guidelines and the product label.
Statistical Analysis
The intent-to-treat (ITT) population included all
randomized patients and was used for the primary
analysis of PFS and all secondary efficacy end points. The
safety population included all patients who received at
least one dose of any study drug.
Full statistical methods are provided in the
Supplementary Methods. Assuming a median PFS of 3
months for the placebo plus paclitaxel (henceforth
referred to as placebo/paclitaxel) arm and also assuming
that alisertib/paclitaxel could improve median PFS to 5
months (40% reduction of hazard), a minimum of 138
PFS events were required for the primary analysis (two-
sided alpha 0.05, power 85%). PFS was tested by using a
two-sided stratified log-rank test to compare arms.
Hazard ratios (HRs) and 95% confidence intervals (CI)
were estimated by using a Cox proportional hazard
regression model stratified by type of relapse and
presence of brain metastases, with treatment arm
included as a factor in the model. Kaplan-Meier survival
curves were provided for each arm. OS and other time-
to-event end points were analyzed by using similar
methods.
Assessment of c-Myc expression by immunohisto-
chemistry was analyzed as (1) percentage of positive
cells or (2) dichotomized readout converted to a binary
variable (positive versus negative) based on modal in-
tensity. For both methods, a Cox proportional hazard
model was used to analyze PFS, with treatment and c-
Myc expression as the main effects. Interactions between
NGS-identified genetic alterations and treatments (ali-
sertib versus placebo) were tested with a Cox propor-
tional hazards model for PFS and OS. The genetic
alterations tested included single-gene mutations
(mutant allele frequency 0.01), pathway gene muta-
tions, and mutation load.
A protocol amendment (January 2015) corrected the
stratification definition of relapse type after primary
treatment so that relapses were recorded “from last
administration of platinum-based chemotherapy” rather
than “from initial response.” To maintain balance, the
primary end point was analyzed by using the original
stratification definition of relapse type. However, a
sensitivity analysis with use of the corrected stratifica-
tion definition was also included.
Results
Patients
A total of 178 patients were enrolled and randomized
to receive alisertib/paclitaxel (n ¼ 89) or placebo/
paclitaxel (n ¼ 89 [Supplementary Fig. 1]). Patient
characteristics at baseline are shown in Table 1. Two
patients in the alisertib/paclitaxel arm were randomized
but did not receive any study drug and were included in
the ITT population analysis only. When the corrected
definition of relapse type (sensitive versus resistant or
refractory disease) was used, 53 (30%) patients had
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their relapse stratification factor changed after initial
classification, and there was a higher ratio of percentage
of sensitive patients in the placebo/paclitaxel arm to that
in the alisertib/paclitaxel arm (42:33) compared with
when the original definition (45:40) was used (see
Table 1). In addition, for five patients in the placebo/
paclitaxel arm who had been enrolled under the original
definition, sufficient data had not been provided to allow
classification under the corrected definition, so
they were excluded from the corrected stratification
analysis.
Efficacy
The median PFS was 3.32 months in the alisertib/
paclitaxel arm versus 2.17 months in the placebo/
paclitaxel arm (HR ¼ 0.77, 95% CI: 0.557–1.067, p ¼
0.113). In the prespecified sensitivity analysis, when the
corrected definition for the stratification factor of
relapse type was used, the HR was 0.71 (95% CI: 0.509–
0.985, p ¼ 0.038; [Fig. 1A]). There were no differences in
PFS between arms based on the presence of metastases,
enrollment region, Eastern Cooperative Oncology Group
performance status, age category, race, or disease stage
(data not shown). Although there was no difference in
PFS for male patients (HR ¼ 1.03, 95% CI: 0.677–1.578,
p ¼ 0.876), there was a marginal difference for female
patients in favor of alisertib/paclitaxel compared with
placebo/paclitaxel (median PFS 4.4 versus 2.6 months
[HR ¼ 0.60, 95% CI: 0.367–0.992, p ¼ 0.043]). For pa-
tients with resistant or refractory relapse (corrected
definition), the median PFS was 2.86 months with ali-
sertib/paclitaxel versus 1.68 months with placebo/
paclitaxel (HR ¼ 0.66, p ¼ 0.037 [Fig. 1B]). For patients
with sensitive relapse (corrected definition), the median
PFS was 3.72 months with alisertib/paclitaxel versus
3.34 months with placebo/paclitaxel, respectively (HR ¼
0.86, 95% CI: 0.493–1.497, p ¼ 0.590).
At data cutoff, there was no significant difference in
OS between arms (Fig. 1C). The median OS was 6.11
months with alisertib/paclitaxel versus 5.42 months
with placebo/paclitaxel. Per protocol, a further OS
Table 1. Demographics and Baseline Disease Characteristics (Intent-to-Treat Population)
Characteristic Alisertib/Paclitaxel (n ¼ 89) Placebo/Paclitaxel (n ¼ 89)
Median age, y (range) 62 (37–81) 62 (46–86)
Male sex, n (%) 51 (57) 50 (56)
Median time since initial diagnosis, mo (range) 7.4 (3–12) 7.8 (3–26)
VALG stage at initial diagnosis, n (%)
Limited 18 (20) 8 (9)
Extensive 61 (69) 62 (70)
Unknown 10 (11) 19 (21)
ECOG PS, n (%)
0 27 (30) 18 (20)
1 62 (70) 71 (80)
Smoking history, n (%)
Never 4 (4) 7 (8)
Former/current 52 (58)/33 (37) 52 (59)/29 (33)
Missinga 0 1 (1)
No prior prophylactic cranial irradiation, n (%) 59 (66) 63 (71)
No brain involvement at baseline, n (%) 62 (70) 63 (71)
Type of relapse after primary treatment (by IVRS), n (%)
Sensitiveb 36 (40) 40 (45)
Resistant/refractoryb 36 (40)/17 (19) 34 (38)/15 (17)
Type of relapse after primary treatment (corrected),c n (%)
Sensitive 29 (33) 35 (42)
Resistant/refractory 41 (46)/19 (21) 33 (39)/16 (19)
Not classifiable or missinga 0 5 (6)
aMissing data were treated as missing and no data imputation was applied.
bSensitive disease is defined as progression of disease observed >90 days from the last dose of first-line platinum-based chemotherapy, resistant disease is
defined as progression of disease observed 90 days after first-line platinum-based chemotherapy, and refractory disease is defined as no objective response
and progression either during or immediately after first-line platinum-based chemotherapy.
cProtocol Amendment 2 (January 2015) corrected the stratification definition for time to relapse to follow standard guidance by counting from date of last dose
of frontline chemotherapy as opposed to by counting from initial response to first-line platinum-based chemotherapy, as originally set out in the protocol; the
stratification factors for the study were corrected accordingly. When the corrected definition of time to relapse for type of relapse after primary treatment
(sensitive versus resistant or refractory disease) was used, 53 patients (30%) had their relapse stratification factor changed after initial classification. In all, 15
patients in the alisertib plus paclitaxel arm and 14 in the placebo plus paclitaxel arm were reassigned from “sensitive” to “resistant or refractory”’ relapse,
and 8 and 11 patients, respectively, were reassigned from “resistant or refractory” to “sensitive” relapse.
ECOG PS, Eastern Cooperative Oncology Group performance status; IVRS, Interactive Voice Response System; VALG, Veterans Administration Lung Study Group.
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analysis, including data from at least 80% of patients,
was conducted on October 15, 2016. Overall, 151 pa-
tients had died at this time, which was an increase of 23
deaths from the previous analysis. The updated median
OS was 6.86 months with alisertib/paclitaxel versus 5.58
months with placebo/paclitaxel (HR ¼ 0.93, 95% CI:
0.652–1.341, p ¼ 0.714; HR with use of the corrected
definition for relapse type ¼ 0.73, 95% CI: 0.520–1.021,
p ¼ 0.064).
The ORR was 22% with alisertib/paclitaxel versus
18% with placebo/paclitaxel (Table 2). The DCR was
58% versus 46%, respectively. For the subgroup of
resistant or refractory patients when the corrected
definition for relapse type was used, the DCR was
significantly higher with alisertib/paclitaxel than with
placebo/paclitaxel (55% versus 33% [odds ratio ¼ 0.40
(range 0.18–0.87), p ¼ 0.020]). The median DOR among
responders was 3.16 months in the alisertib/paclitaxel
arm and 2.79 months in the placebo/paclitaxel arm (see
Table 2). The median time to progression was 3.58
months with alisertib/paclitaxel versus 2.60 months
with placebo/paclitaxel (HR ¼ 0.67, p ¼ 0.038) (see
Table 2).
Exploratory Correlative Biomarker Studies
In all, 46 tumor tissue samples were evaluable for the
c-Myc expression by immunohistochemistry analysis; 33
(72%) were positive (a modal intensity of 1þ, 2þ, or
3þ) for c-Myc expression and 13 (28%) were negative
(modal intensity ¼ 0). PFS by c-Myc expression is shown
in Fig. 1D and 1E. In c-Myc–positive patients, the median
PFS was 4.64 months with alisertib/paclitaxel (n ¼ 17)
versus 2.27 months with placebo/paclitaxel (n ¼ 16)
(HR ¼ 0.29, 95% CI: 0.12–0.72). In c-Myc–negative pa-
tients, the median PFS was 3.32 months with alisertib/
paclitaxel (n ¼ 6) versus 5.16 months with placebo/
paclitaxel (n ¼ 7) (HR ¼ 11.8, 95% CI: 1.52–91.2). c-Myc
expression was strongly associated with improved PFS
when c-Myc was evaluated as a continuous variable of
percentage of cells staining positive (pcontinuous ¼
0.0045) or a binary (positive versus negative) mode
(pbinary ¼ 0.0006).
Out of 176 patients, 155 (88%) provided plasma
samples that were processed for NGS analysis of ctDNA.
In all, 142 patient samples (81%) were successfully
sequenced and genetic alterations were identified from
140 patients (80%) (Supplementary Fig. 1). The full
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Figure 1. Clinical outcomes for the intent-to-treat population and according to resistant or refractory relapse and c-Myc
expression. (A) Progression-free survival (PFS) in all patients. (B) PFS in patients with resistant or refractory relapse. (C)
Overall survival in all patients. (D) PFS in patients positive for c-Myc expression. (E) PFS in patients negative for c-Myc
expression. (A–C) Hazard ratios (HRs), 95% confidence intervals (CIs), and p values for the comparison of alisertib plus
paclitaxel versus placebo plus paclitaxel are shown per protocol and with use of the corrected definition for the stratification
factor of relapse type.
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results from this genetic profiling are provided in the
Supplementary Results (Supplementary Figs. 2–6 and
see also Supplementary Fig. 1). The genetic mutation
profiles revealed from the SCLC plasma ctDNA samples
were concordant with those previously identified in
SCLC primary tumor tissue,24 matching the mutational
frequency trends in characterized genes, such as tumor
protein p53 gene (TP53), retinoblastoma 1 gene (RB1),
formin 2 gene (FMN2), notch receptor 1 gene (NOTCH1),
collagen type XXII alpha 1 chain gene (COL22A1), spec-
trin repeat containing nuclear envelope protein 1 gene
(SYNE1), CREB binding protein gene (CREBBP), ATRX
chromatin remodeler gene (ATRX), notch receptor
3 gene (NOTCH3), regulating synaptic membrane
exocytosis 2 gene (RIMS2), and contactin associated
protein-like 2 gene (CNTNAP2) (Fig. 2A). The mutation
spectrum of the key genes also showed high concor-
dance (see Supplementary Fig. 3). The correlative anal-
ysis of clinical outcomes (PFS and OS) was assessed in
relation to (1) individual gene mutations, (2) biological
pathway gene mutations, and (3) overall mutation load.
At the individual gene mutation level, five of the
mutated genes were found to have marginal significance
to PFS or OS in the alisertib/paclitaxel arm: RB1, ade-
nylate cyclase 1 gene (ADCY1), CNTNAP2, zinc finger
protein 217 gene (ZNF217), and BCL associated tran-
scription factor 1 gene (BCLAF1) (Fig. 2B). When
grouped by biological pathway (see Supplementary
Figs. 4 and 5), mutations in genes involved in cell cycle
regulation (cyclin-dependent kinase 6 gene [CDK6],
retinoblastoma-like 1 gene [RBL1], retinoblastoma-like 2
gene [RBL2], and retinoblastoma 1 gene [RB1]) were
significantly associated with improved PFS (p ¼ 0.0011)
and OS (p ¼ 0.00096) after alisertib/paclitaxel treat-
ment. No such association was shown for mutated genes
involved in NOTCH (NOTCH1, NOTCH2, and NOTCH3) or
phosphoinositide 3-kinase (KIT proto-oncogene receptor
tyrosine kinase gene [KIT], phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha gene
[PIK3CA], phosphatase and tensin homolog gene [PTEN],
tumor protein p73 gene [TP73]) signaling, or histone
modifications (CREBBP and E1A binding protein p300
gene [EP300]) (see Supplementary Fig. 5). Patients with
mutations in cell cycle regulators (“mutant”) had
improved median PFS (3.68 versus 1.80 months [HR ¼
0.395, 95% CI: 0.239–0.654, p ¼ 0.0003]) (Fig. 3A and
3B) and OS (7.20 versus 4.47 months [HR ¼ 0.427, 95%
CI: 0.259–0.704, p ¼ 0.00085]) with alisertib/paclitaxel
(n ¼ 40) compared with placebo/paclitaxel (n ¼ 47)
(Fig. 3C and 3D). Conversely, patients without mutations
in cell cycle regulators (“wild type”) had no improve-
ment in median PFS (2.63 versus 2.60 months [HR ¼
1.31, 95% CI: 0.736–2.33, p ¼ 0.359]) (see Fig. 3A and
3B) or OS (4.47 versus 5.95 months [HR ¼ 1.70, 95% CI:
0.865–3.33, p ¼ 0.124]) with alisertib/paclitaxel (n ¼
28) versus with placebo/paclitaxel (n ¼ 25) (see Fig. 3C
and 3D). Across the 140 samples sequenced, 2151 mu-
tations were identified, with a mean mutational load of
12.93 mutations per megabase pair of panel sequenced
and a median value of 8.52 mutations per megabase pair
(see Supplementary Fig. 6). Correlation between muta-
tional load and PFS or OS in the alisertib arm was
marginally significant for OS (p ¼ 0.025) but not for PFS
(p ¼ 0.103). Notably, patient samples with mutations in
cell cycle regulation genes had a significantly higher
mutational load (a mean of 19.03) compared with those
without cell cycle regulation gene mutations (a mean of
9.06) (p < 0.0001) (see Supplementary Fig. 6).
Safety and Tolerability
The median numbers of cycles received in the ali-
sertib/paclitaxel and placebo/paclitaxel arms were 3
Table 2. Best Overall Response Rate (ITT Population), Duration of Response, and Time to Progression
Variable
Alisertib/Paclitaxel
(n ¼ 89)
Placebo/Paclitaxel
(n ¼ 89)
OR/HR (95% CI);
p Value
Response, n (%)
ORR (CR þ PR) 20 (22) 16 (18) 0.74 (0.35–1.55); 0.406
CR 1 (1) 0 NE
PR 19 (21) 16 (18) NE
Stable disease 49 (55) 44 (49) NE
DCR (CR þ PR þ stable disease 8 weeks) 52 (58) 41 (46) 0.59 (0.32–1.08); 0.077
PD 13 (15) 23 (26) NE
No on-study imaginga 7 (8)b 6 (7)c NE
Median DOR (responders), mo (95% CI) 3.16 (2.76–4.64) 2.79 (1.91–5.82) NE
Median TTP (ITT), mo (95% CI) 3.58 (2.86–4.41) 2.60 (1.74–3.45) 0.67 (0.462–0.982); 0.038
aMissing data were treated as missing and no data imputation was applied.
bThree patients died before on-study imaging, two patients were not assessed, and two patients were not dosed.
cFour patients died before to on-study imaging, one patient was not assessed, and one patient was too ill for imaging.
CI, confidence interval; CR, complete response; DCR, disease control rate; DOR, duration of response; HR, hazard ratio; ITT, intent-to-treat population; NE, not
evaluated; OR, odds ratio; ORR, objective response rate; PD, disease progression; PR, partial response; TTP, time to progression.
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Figure 2. Association between gene mutations and clinical outcomes. (A) Gene mutation frequencies identified in this study
by using circulating tumor DNA (ctDNA) were compared with those reported previously in primary tumor tissue samples from
patients with SCLC.24 Mutation frequencies for the 20 most commonly mutated genes are shown. (B) The interaction between
genetic alterations and clinical outcomes (progression-free survival [PFS] and overall survival [OS]) was tested by using a Cox
proportional hazards model. The p values and false discovery rates (FDRs) for the association with outcome are shown.
Mutations in retinoblastoma 1 gene (RB1), BCL associated transcription factor 1 gene (BCLAF), contactin associated protein-
like 2 gene (CNTNAP2), adenylate cyclase 1 gene (ADCY1), and zinc finger protein 217 gene (ZNF217) were independently
associated with alisertib plus paclitaxel versus with placebo plus paclitaxel efficacy, as defined by hazard ratios for PFS and
OS. Abbreviations: TP53, tumor protein p53 gene; FMN2, formin 2 gene; NOTCH1, notch receptor 1 gene; COL22A1, collagen
type XXII alpha 1 chain gene; SYNE1, spectrin repeat containing nuclear envelope protein 1 gene; TP73, tumor protein p73
gene; CREBBP, CREB binding protein gene; ERICH3, glutamate rich 3 gene; KIAA1211, KIAA1211 gene (now known by the gene
symbol CRACD); TMEM132D, transmembrane protein 132D gene; COL11A1, collagen type XI alpha 1 chain gene; ATRX, ATRX
chromatin remodeler gene; NOTCH3, notch receptor 3 gene; SPHKAP, SPHK1 interactor, AKAP domain containing gene; RIMS2,
regulating synaptic membrane exocytosis 2 gene; ZDBF2, zinc finger DBF-type containing 2 gene; AR, androgen receptor
gene; CNTNAP2, contactin associated protein 2 gene; EP300, E1A binding protein p300 gene.
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(range 1–9) and 2 (range 1–11), respectively. Diarrhea
and fatigue were the most common adverse events
(AEs); both were reported more frequently with ali-
sertib/paclitaxel than with placebo/paclitaxel. Grade 3
or higher AEs were more common with alisertib/pacli-
taxel (76%) than with placebo/paclitaxel (51%),
including the most common individual grade 3 or higher
AE, neutropenia (Table 3). Drug-related AEs were also
more common with alisertib/paclitaxel than with pla-
cebo/paclitaxel (see Table 3); the most common drug-
related grade 3 or higher AEs were neutropenia, febrile
neutropenia, leukopenia, anemia, diarrhea, and
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Figure 3. Clinical outcomes according to treatment and mutations in cell cycle regulation pathway genes. (A) Cox propor-
tional hazard regression analysis of progression-free survival (PFS) in patients with (mutant) and without (wild-type) mu-
tations in cell cycle pathway genes, respectively. In each subgroup, the hazard ratio (HR) between the two treatment arms
(alisertib plus paclitaxel versus placebo plus paclitaxel) was estimated, along with the 95% confidence interval (CI) and p
value. (B) Kaplan-Meier plots of PFS in mutant and wild-type patients, respectively. The p value in this panel is the interaction
effect between treatment group and mutation status and is calculated by testing the difference between the HRs for the two
subgroups. (C) Cox proportional hazard regression analysis of overall survival (OS) in mutant and wild-type patients,
respectively. In each subgroup, the HR between the two treatment arms (alisertib plus paclitaxel versus placebo plus
paclitaxel) was estimated, along with the 95% CI and p value. (D) Kaplan-Meier plots of OS in mutant and wild-type patients,
respectively. The p value in this panel is the interaction effect between treatment group and mutation status and is
calculated by testing the difference between the HRs for the two subgroups.
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stomatitis, which were all reported more frequently with
alisertib/paclitaxel than with placebo/paclitaxel. Simi-
larly, in the alisertib/paclitaxel arm, 38 patients (44%)
reported a serious AE (SAE) and 28 (32%) reported a
drug-related SAE, compared with 28 patients (31%) and
six (7%), respectively, in the placebo/paclitaxel arm. The
most common (5% of patients in either treatment arm)
all-cause SAEs with alisertib/paclitaxel were febrile
neutropenia (10%), neutropenia (6%), diarrhea (6%),
and stomatitis (5%). There were no SAEs of febrile
neutropenia, neutropenia, or diarrhea with placebo/
paclitaxel; one patient (1%) reported an SAE of
stomatitis.
In the alisertib/paclitaxel and placebo/paclitaxel arms,
14 patients (16%) and five (6%) discontinued study
treatment because of an AE, 33 patients (38%) and nine
(10%) had a dose reduction because of an AE, and 12
patients (14%) and 11 (12%) died during the study
(within 30 days of last dose). Four of these deaths, all in
the alisertib/paclitaxel arm, were assessed as drug related,
including one each due to neutropenic sepsis, sepsis,
febrile neutropenia, and septic shock (see Table 3).
Table 3. Most Frequently Reported All-Cause and Drug-Related Treatment-Emergent AEs, Occurring in at Least 15% (All-
Cause) or at Least 10% (Drug-Related) of Patients Overall (Any Grade) in Either Arm, Respectively, with the Corresponding
Grade 3 or higher AEs (Safety Population), and All Drug-Related Fatal AEs
AE
Alisertib/Paclitaxel (n ¼ 87) Placebo/Paclitaxel (n ¼ 89)
Any Grade Grade 3 Any Grade Grade 3
All-cause AE, n (%) 86 (99) 66 (76) 85 (96) 45 (51)
Diarrhea 51 (59) 14 (16) 18 (20) 1 (1)
Fatigue 38 (44) 9 (10) 29 (33) 5 (6)
Nausea 29 (33) 2 (2) 30 (34) 4 (4)
Anemia 38 (44) 12 (14) 18 (20) 3 (3)
Neutropenia 43 (49) 35 (40) 7 (8) 5 (6)
Vomiting 28 (32) 2 (2) 21 (24) 3 (3)
Decreased appetite 29 (33) 3 (3) 19 (21) 3 (3)
Dyspnea 21 (24) 4 (5) 19 (21) 2 (2)
Stomatitis 29 (33) 12 (14) 6 (7) 2 (2)
Cough 17 (20) 0 17 (19) 0
Constipation 8 (9) 1 (1) 21 (24) 0
Asthenia 14 (16) 3 (3) 11 (12) 0
Dizziness 14 (16) 0 8 (9) 0
Alopecia 14 (16) 0 5 (6) 0
Leukopenia 13 (15) 7 (8) 5 (6) 2 (2)
Decreased neutrophil count 14 (16) 11 (13) 4 (4) 1 (1)
Weight decreased 13 (15) 0 5 (6) 0
Drug-related AE, n (%) 81 (93) 58 (67) 72 (81) 22 (25)
Diarrhea 44 (51) 13 (15) 11 (12) 1 (1)
Fatigue 32 (37) 7 (8) 23 (26) 3 (3)
Nausea 24 (28) 2 (2) 26 (29) 4 (4)
Neutropenia 41 (47) 33 (38) 7 (8) 5 (6)
Anemia 31 (36) 9 (10) 14 (16) 1 (1)
Vomiting 23 (26) 2 (2) 14 (16) 2 (2)
Stomatitis 28 (32) 11 (13) 6 (7) 2 (2)
Decreased appetite 21 (24) 3 (3) 13 (15) 1 (1)
Leukopenia 13 (15) 7 (8) 5 (6) 2 (2)
Alopecia 12 (14) 0 5 (6) 0
Neutrophil count decreased 13 (15) 10 (11) 4 (4) 1 (1)
Febrile neutropenia 11 (13) 11 (13) 0 0
WBC count decreased 11 (13) 11 (13) 1 (1) 1 (1)
Asthenia 9 (10) 3 (3) 6 (7) 0
Drug-related fatal AE, n (%)
Neutropenic sepsis — 1 (1) — 0
Sepsis — 1 (1) — 0
Febrile neutropenia — 1 (1) — 0
Septic shock — 1 (1) — 0
AE, adverse event; WBC, white blood cell.
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Discussion
In this study of alisertib/paclitaxel versus placebo/
paclitaxel as second-line therapy in patients with
advanced SCLC, the primary end point of PFS in the ITT
population was not met, but PFS was significantly
improved when analyzed on the basis of the corrected
definition of relapse type after first-line therapy (as
intended by the protocol), with a positive trend favoring
alisertib/paclitaxel (p ¼ 0.038). However, this PFS
benefit was not clinically meaningful. Similarly, the
subgroup analysis of type of relapse after first-line
therapy (corrected definition) demonstrated a statisti-
cally significant improvement in PFS with alisertib/
paclitaxel over that with placebo/paclitaxel in patients
with resistant or refractory relapsed SCLC (p ¼ 0.037).
However, the primary analysis of PFS conducted by us-
ing the original stratification definition of relapse type
was not significant on statistical testing. Despite a trend
in favor of alisertib/paclitaxel, there was no significant
difference in OS between arms; however, the study was
not powered to show an OS advantage. Notably, the
correlative biomarker studies indicated that both c-Myc
expression and mutations in cell cycle regulators (CDK6,
RBL1, RBL2, and RB1) showed strong correlation with
improved clinical outcomes (PFS and OS) in patients
with SCLC who were receiving alisertib/paclitaxel. These
findings are consistent with the mechanism of action of
alisertib as a mitotic inhibitor disrupting cell cycle pro-
gression through mitosis. Thus, c-Myc expression or cell
cycle gene mutations may serve as predictive bio-
markers for alisertib.
When the results are interpreted, there are points to
consider. Although not the primary end point, the
sensitivity analysis of PFS using the corrected definition
of relapse type may represent a more clinically relevant,
scientifically valid approach. In the PFS sensitivity anal-
ysis with use of the corrected definition of relapse type,
patients without a stratification factor were excluded,
improving internal validity. There was also a higher ratio
of sensitive patients in the placebo/paclitaxel arm to
sensitive patients in the alisertib/paclitaxel arm (42:33),
as compared with when the original definition was used
(45:40); therefore, the original analysis favored placebo/
paclitaxel. Finally, doses of paclitaxel were different in
each arm to account for the pharmacodynamic synergy
of paclitaxel with alisertib.
The median PFS with placebo/paclitaxel was slightly
shorter than in a previous study of second-line paclitaxel
monotherapy in patients with SCLC (4.76 months),25
whereas the median OS was in line with values in pre-
vious reports (3.3–5.8 months).25-27 A longer interval
between restaging scans could lead to overestimation of
PFS, and the shorter PFS duration in our study
potentially reflects the more rigorous restaging scan
schedule (every 4 weeks for the first six cycles), which
enabled more accurate estimation of PFS than in previ-
ous studies.
Although cross-trial comparison should be
approached with caution, the response rate of 22%
observed with the alisertib/paclitaxel combination in the
study is comparable to the 21% response rate associated
with single-agent alisertib in 48 patients with SCLC in a
phase 1/2 study,23 which may suggest that synergy of
the combination is limited in this treatment setting.
Because of the overlapping toxicity profile for ali-
sertib and paclitaxel, there was a higher incidence of
grade 3 or higher AEs and drug-related AEs with this
combination versus with paclitaxel alone. Increased
toxicity is a concern in this treatment setting, in which
many patients are not clinically robust. Clinically
manageable hematologic events were among the most
frequent drug-related grade 3 or higher treatment-
emergent AEs in patients who received alisertib/pacli-
taxel; of particular note, a high rate of grade 3 or higher
neutropenia (38%) was observed. Overall, 44 patients in
the study received myeloid growth factor support to
manage neutropenia (34 patients in the alisertib/pacli-
taxel arm and 10 patients in the placebo/paclitaxel arm).
Rates of on-study deaths were similar in both arms, but
four AE-related deaths (due to febrile neutropenia,
neutropenic sepsis, sepsis, and septic shock) occurred
only with alisertib/paclitaxel.
AAK binds to c-Myc and prevents its degradation,
thereby enhancing its growth-promoting effect in cancer
cells.16,17 Conversely, pharmacologic inhibition of AAK in
preclinical studies results in greater growth inhibition in
cell lines harboring MYC amplification.13,14 We therefore
anticipated that patients whose tumors harbored high c-
Myc expression would be susceptible to an AAK inhibitor
(as seen in preclinical studies).28 Moreover, as c-Myc
alteration may be correlated with poor response to
chemotherapy, we anticipated that patients with resis-
tant or refractory relapse would derive greater benefit.
Consistent with this hypothesis, alisertib/paclitaxel
showed significant benefit over placebo/paclitaxel in
patients with resistant or refractory relapse and in pa-
tients with c-Myc expression. Although the numbers
were low and the results need to be reproduced in a
larger independent study, we expect that enrichment
strategies for these patient subsets could aid further
development of alisertib in SCLC.
With respect to genetic biomarkers, patients treated
with alisertib/paclitaxel who had mutations in cell cycle
regulator genes, including CDK6, RBL1, RBL2, and RB1,
had significantly improved PFS and OS compared with
those who received placebo/paclitaxel. Previous
genomic landscape studies have implicated cell cycle
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regulation genes as being commonly mutated in
SCLC.24,29 Our findings suggest a predictive value of
these mutations with alisertib/paclitaxel treatment for
SCLC. Interestingly, patients with mutated cell cycle
regulators had worse outcomes in response to placebo/
paclitaxel treatment; the implications of these findings
warrant further investigation. Our study results are
consistent with, and provide validation, of the findings
from two preclinical reports in Cancer Discovery, which
describe a synthetic lethal relationship between RB1
mutations and inhibition of AAK or Aurora B kinase.30,31
The predictive value of cell cycle mutations for alisertib
treatment in other diseases is also of interest and worth
further exploration. Importantly, our data highlight the
emerging role of NGS profiling of plasma ctDNA for
identifying novel predictive biomarkers.
No predictive value was demonstrated in genetic al-
terations in other cell cycle progression genes implicated
in SCLC, such as amplification of Aurora kinase A gene
(AURKA) and MYC10,17,32,33 (data not shown). Similarly,
pathway mutations in genes implicated in NOTCH and
phosphoinositide 3-kinase signaling, and histone modi-
fications, showed no association with PFS or OS in
response to alisertib treatment. As these parameters
were established retrospectively, the study was not
optimized for this metric.
A key limitation of our study was the failure to use
a validated biomarker for prospective patient selection.
Although post hoc biomarker interrogation supported
c-Myc expression and mutations in cell cycle regulator
genes as promising biomarkers, these observations
require more rigorous prospective testing and valida-
tion. Additionally, the study failed to demonstrate
survival benefit of alisertib/paclitaxel compared with
placebo/paclitaxel. Patients entering this study were
stratified by platinum sensitivity status based on data
available at the time, which suggested that platinum
sensitivity status was correlated with efficacy out-
comes. However, data from studies in relapsed SCLC
published during the conduct of this trial suggest that
platinum sensitivity may not be strongly associated
with efficacy outcomes and that other prognostic sub-
groups could be more relevant in study designs.34
Another limitation was that the comparator arm in
this study was placebo/paclitaxel. At the time of this
study’s design, topotecan was the only agent approved
in the relapsed setting by the U.S. Food and Drug
Administration (FDA),6,35 having demonstrated symp-
tom reduction and less hematologic toxicity than with
cyclophosphamide, doxorubicin, and vincristine,36 and
survival benefit over best supportive care.37 Single-
agent paclitaxel is frequently used off-label as a stan-
dard treatment for relapsed SCLC, and paclitaxel was
chosen as the comparator in this study, rather than
topotecan, because of the higher toxicity associated
with topotecan, particularly the overlapping toxicity of
neutropenia with alisertib, and the existence of pre-
clinical and clinical data for the alisertib/paclitaxel
combination.19 Recently, other agents have shown
similar or improved efficacy compared with topotecan,
including amrubicin8 and cisplatin, etoposide, and iri-
notecan,38 and in August 2018, nivolumab received
accelerated approval by the FDA for patients with
metastatic SCLC with progression after platinum-based
chemotherapy and at least one other line of therapy.39
Approval was based on findings from the open-label,
multicohort CHECKMATE-032 study (NCT01928394),
which reported an ORR of 12% (95% CI: 6.5–19.5) in
109 patients (w65% with platinum-sensitive SCLC,
defined as progression 90 days after the last dose of
platinum-containing therapy), with 77% having a DOR
of at least 6 months when treated with nivolumab with
or without ipilimumab.39 Further treatment options
continue to emerge for SCLC, including immuno-
therapy; in 2019, FDA approvals for have been granted
for pembrolizumab in relapsed or refractory SCLC,
based on the results of the KEYNOTE-028
(NCT02054806) and KEYNOTE-158 (NCT02628067)
studies,40,41 and for atezolizumab in combination with
chemotherapy in the frontline treatment of extensive-
stage SCLC, based on the IMpower133 trial
(NCT02763579).42 There were seven patients who had
received treatment with immunotherapy before start-
ing our study (two in the alisertib/paclitaxel arm and
five in the placebo/paclitaxel arm); postprogression
treatment information was not collected. Despite the
emerging range of treatment options, topotecan re-
mains the standard therapy in the second-line setting.
Whether the efficacy signal observed in the present
study is sufficient to support a definitive superiority
trial in comparison with topotecan in unselected pa-
tients is difficult to ascertain, particularly in light of the
negative result of the phase II trial of cabazitaxel
versus topotecan in a similar population of patients
with relapsed SCLC.7 However, a biomarker-enrichment
strategy using c-Myc expression or mutations in cell
cycle regulator genes could enhance the likelihood of
success of such a comparative study.
In conclusion, alisertib/paclitaxel showed a modest
efficacy signal as second-line therapy for SCLC. Because
of the overlapping safety profile for alisertib and pacli-
taxel, grade 3 or higher AEs and drug-related AEs were
more frequent with the combination than with paclitaxel
alone. The predictive value of c-Myc expression and cell
cycle gene mutations for AAK inhibitor susceptibility is
promising, but prospective testing and validation are
required. These results, along with those from a previous
phase II study demonstrating activity of alisertib
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monotherapy in patients with relapsed or refractory
SCLC,23 may warrant further testing in a larger study
with predictive biomarker enrichment strategy.
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